Lapo Alinari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lapo Alinari has a total of 382 co-authors. Here are the top co-authors by number of shared publications:
- Alexey V. Danilov
City of Hope National Medical Center
40 shared publications - Allison Berger
Takeda Development Center Americas Inc., Lexington, Massachusetts
40 shared publications - Carly Roleder
City of Hope National Medical Center 1 , Duarte, California
40 shared publications - Geoffrey Shouse
Department of Hematology and Hematopoietic Cell Transplantation City of Hope National Medical Center Duarte California USA
40 shared publications - Lili Wang
Department of Systems Biology, Beckman Research Institute, City of Hope, Duarte, USA
40 shared publications - Nathan D. Pennock
Department of Radiation Medicine, School of Medicine, Oregon Health & Science University, Portland, OR, USA
40 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 2. Trispecific CAR T Cell Persistence by gag gene PCR (single dose infusion versus split dose infusion).
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 2. Trispecific CAR T Cell Persistence by gag gene PCR (single dose infusion versus split dose infusion).
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 4. Immunophenotypic and functional characteristics CD8+ CAR + T cells and CD4+ CAR + T cells in post-CAR T infusion PBMCs at Day 7.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 4. Immunophenotypic and functional characteristics CD8+ CAR + T cells and CD4+ CAR + T cells in post-CAR T infusion PBMCs at Day 7.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 1. Trial Schema.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 1. Trial Schema.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Table 2. Toxicity and other clinical outcomes.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Table 2. Toxicity and other clinical outcomes.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 6. Trispecific CAR + T cell Gating Strategy for spectral flow cytometry.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 6. Trispecific CAR + T cell Gating Strategy for spectral flow cytometry.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 3. Statistical Analysis (Area Under the Curve) Trispecific CAR T Cell Persistence by PCR Data.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 3. Statistical Analysis (Area Under the Curve) Trispecific CAR T Cell Persistence by PCR Data.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 5: Immunophenotypic and functional characteristics CD8+ CAR + T cells and CD4+ CAR + T cells in Post-CAR T PBMCs at Day 14.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 5: Immunophenotypic and functional characteristics CD8+ CAR + T cells and CD4+ CAR + T cells in Post-CAR T PBMCs at Day 14.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Table 1. Representativeness of Study Participants.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Table 1. Representativeness of Study Participants.